Background/Aims: Cartilaginous endplate (CEP) degeneration is an important cause for intervertebral disc (IVD) degeneration that leads to low-back pain. The identification of compounds that may prevent CEP degeneration is of interest for the prevention of IVD degeneration. Methods: Catabolic protease expression in the CEP of disc degeneration patients was first assessed. The toxicity, function and underlying mechanism of lycorine (LY) on CEP-derived chondrocytes degeneration were assessed in vitro by flow cytometry analysis and western blotting. The concentration and function of LY in rat-tail disc-degeneration models were also assessed by HPLC (High Performance Liquid Chromatography) quantification and histological analysis. Results: In CEP cells, Interleukin (IL)-1β upregulated the expression of matrix metalloproteinase (MMP)-3, MMP-13, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-4 and ADAMTS-5 that is critical for the degradation of cartilage extracellular matrix. Interestingly, LY suppressed the expression of these enzymes via the inhibition of nuclear factor-κB (NFκB) signalling and thus prevented IL-1β-induced endplate cell degeneration in vitro. More importantly, LY also reduced the expression of MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 in CEP and exerted a protective effect on both CEP and nucleus pulposus (NP) degeneration. In addition to its inhibitory effect on matrix-degrading protease expression, LY treatment also reduced positive regulators of proinflammatory cytokines, such as MIF, which can be secreted by CEP cells and subsequently target NP cells. Conclusion: LY could serve as a potential drug for treating IVD disease.
Introduction
Musculoskeletal disorders of the spine, particularly low-back pain, diminish the quality of daily life [1, 2] . Intervertebral disc (IVD) degeneration is regarded as a predominant pathogenic process leading to low-back pain [3] [4] [5] . Numerous inflammatory factors and proteolytic enzymes are involved in IVD degeneration [6] [7] [8] . Interleukin (IL)-1β is one of the major cytokines that increases the expression of MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5, and it plays a key role in the degeneration of the nucleus pulposus (NP) [9] [10] [11] [12] [13] [14] [15] [16] [17] and cartilaginous endplate (CEP) [18, 19] . The underlying molecular mechanism of IL-1β is mainly mediated by activating the NF-κB-dependent signalling pathway [8, 20] and the mitogen-activated protein kinase (MAPK) signalling pathway [21] [22] [23] [24] [25] .
Increasing numbers of natural compounds exhibited anti-inflammatory effects by counteracting with IL-1β and are proposed for the treatment of IVD degeneration. However, NP cells are the most studied cellular targets in these studies [26] [27] [28] [29] [30] , and intradiscal microinjection is used for drug administration and may act as an additional precipitating factor of IVD degeneration, which limits its clinical application.
The CEP is a thin layer of hyaline bridging between the disc and the vertebral bones [31] . The CEP not only provides biomechanical support by dispersing the pressure between discs [32] but also transports nutrients and metabolites from the vertebral capillaries to the IVDs [32] . Thus, CEP degeneration, including increased calcification and proteoglycan loss, could impede nutrients transportation and alter mechanical transduction, resulting in failure to maintain both the material and metabolic equilibrium in NP [33, 34] . IVD degeneration models are also established by inducing ischaemic sub-endplates [35, 36] . Furthermore, the degenerated CEP can act as a potential source of inflammatory mediators, such as tumour necrosis factor (TNF)-α, IL-1β, IL-6, and macrophage inhibition factor (MIF) [5] . Among these cytokines, MIF [5, 37] not only plays a role in CEP degeneration [37] [38] [39] [40] but also functions as a positive regulator of proinflammatory cytokines (e.g., TNF-α, IL-1β, and IL-6) and thus stimulates adjacent disc tissue degeneration. More importantly, the cartilage canal and vascular buds in the vertebral endplate are specific fine structures [41] [42] [43] that can transport drugs to vertebral endplate by systemic administration [44] [45] [46] [47] [48] , rendering the CEP as an ideal drug target for reducing IVD degeneration. Together, the aforementioned findings collectively suggest that the CEP represents a potential therapeutic target for the treatment of IVD diseases [49, 50] .
Lycorine (LY) is the most abundant alkaloid isolated from the Amaryllidaceae family of plants [51] and can perform diverse biological functions, including anti-tumour [51] , anti-viral [52] and anti-inflammatory [53, 54] functions. In addition, LY suppresses the IL-1β-induced expression of MMP-3 and MMP-13 in articular chondrocytes [55] . However, the effect and underlying mechanism of LY on CEP chondrocyte degeneration, as well as its function in intervertebral disc degeneration have not yet been explored. Thus, the aim of the present study was to explore the potential therapeutic effect of LY on the prevention of IVD degeneration.
Materials and Methods

Immunohistochemical (IHC) staining and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis of human CEP tissue
The present study was approved by the Ethics Committee of Sir Run Run Shaw Hospital, and informed consent was obtained from all patients. Samples of degenerated IVD tissue (Pfirrmann grades 3-5, n = 25) were obtained from patients undergoing lumbar interbody fusion for the treatment of chronic low-back pain. Non-degenerated IVD tissue (Pfirrmann grades 1-2, n = 7) was obtained from patients undergoing internal fixation for the treatment of lumbar fracture.
CEP tissues were isolated by carefully dissecting the annulus fibrous tissues, bone fragments and nucleus pulposus (for all online suppl. material, see www.karger.com/doi/10.1159/000487457, Suppl. 
RNA extraction and RT-qPCR
CEP and NP cells were plated in 6-well plates (6×10 5 cells/well) and total RNA was extracted after treatment for 24 h with 10 ng/ml IL-1β (Sigma-Aldrich) plus LY (0, 0.05, 0.1, 0.2, 0.4 μΜ); subsequently, three different samples were used for each RT-qPCR. The rat primer sequences are listed (see suppl. material) in Suppl. Table 1 .
Western blotting CEP cells were seeded into 6-well plates (6×10 5 cells/well) and treated with IL-1β (10 ng/ml) plus LY (0, 0.05, 0.1, 0.2, 0.4 μΜ) for 48 h. Next, total protein was directly extracted using RIPA lysis buffer (SigmaAldrich) containing a protease-inhibitor cocktail; supernatants were collected after centrifuging the lysates at 12, 000 × g for 15 min, and protein concentrations were determined using a BCA kit (Bio-Rad Laboratories, Inc.). Proteins were separated on 10% SDS-PAGE gels and electroblotted onto polyvinylidene fluoride membranes, which were blocked (2 h) with 5% (w/v) non-fat dry milk in Tris-buffered saline containing Tween (TBST). Next, the membranes were incubated (overnight, 4°C) with antibodies against MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5, washed thrice with TBST, and then incubated with secondary antibodies (2 h, room temperature). Immuno-reactive bands were detected using an electrochemical luminescence reagent (Millipore, USA) and visualized using the LAS-4000 Imaging System from Fujifilm (Japan).
To investigate the effects of IL-1β and LY on signalling pathway, cells were treated with or without 0.4 μM LY for 2 h and then stimulated with IL-1β (10 ng/ml) for 0, 5, 10, 20, 30, or 60 min at 37°C. In subsequent western blotting, antibodies against these targets were used: c-Jun N-terminal kinase (JNK) (Abcam, ab17946); p-JNK (sc-6254), p-P38 (sc-7973), P38 (sc-535), IκB-α (sc-847), p-IκB-α (sc-8404), extracellular signal-regulated kinase (ERK; 4695P), p-ERK (CST, 4370P) and β-actin (sc-47778) (Santa Cruz Biotechnology).
To investigate the signalling upstream of NF-κB, CEP cells were treated with or without 0.4 μΜ LY for 2 h and then with IL-1β (10 ng/ml) for 30 min. Antibodies against these targets were used: IκB kinase (IKK)-β (ab124957), IKK-α (ab32041), phospho-TAK1 (transforming growth factor-β-activated kinase 1 (ab109404); TAK1 (ab109526) and phospho-IKK-α/β (Abcam, 16A6).
Nuclear and cytoplasmic proteins were separated using a Nuclear/Cytosolic Fractionation assay kit (KWBIO) after treating cells with IL-1β (10 ng/ml) with or without LY (0.4 μΜ) for 30 min, and western blotting was performed with anti-NF-κB p65 (D14E12, CST) and anti-GAPDH and anti-histone H3 (sc-47724 and sc-34262, Santa Cruz Biotechnology).
To investigate the molecular interactions between the CEP and NP, CEP and NP cells were treated with IL-1β (10 ng/ml) with or without LY (0.4 μΜ) and then RNA and protein were extracted. RT-PCR and western blotting were performed. The antibodies used were against TNF-α (ab6671), IL-6 (ab9324), and MIF (ab7207) and IL-1β (sc-7884).
Cell transfection and luciferase reporter
To confirm the effect of LY on IκB-α signalling, we overexpressed IKK-β through transfection, and treated the cells first for 2 h with or without 0.4 μΜ LY and then with IL-1β (10 ng/ml) for 30 min. Western blotting was then used to quantify IKK-β, IKK-α, phospho-IKK-α/β. ADAMTS-4, ADAMTS-5, MMP-13, and MMP-3 were quantified after 48h of LY and IL-1β treating.
To demonstrate direct inhibition of NF-κB signalling, CEP cells were analyzed using luciferase reportergene assays. CEP cells were seeded into 96-well plates (3×10 3 cells/well), and transfected with pNF-κB-luc (Beyotime, Shanghai, China), which contains NF-κB binding motifs (GGGAATTTCC), by using Lipofectamine 3000 (Invitrogen, USA). Next, the cells were treated with LY (0, 0.1, 0.2, 0.4 μM) for 2 h and stimulated with IL-1β (10 ng/ml) for another 24 h. Luciferase activity was measured by using a dual-luciferase assay kit according to the manufacturer's protocol (Beyotime).
Proteoglycan content analysis
Methanol-fixed CEP and NP monolayers were stained with Alcian blue to assess the proteoglycan content in the ECM in vitro. Alcian blue (LEAGENE, Beijing, China) were stained according to the protocol. Total amounts of proteoglycan released into the culture medium and in the ECM were also measured using the 1, 9-dimethylmethylene blue (DMMB; Sigma) colorimetric assay, as described [56] . Briefly, CEP and NP cells (3 wells/treatment) were lyophilized to a constant weight and digested in papain buffer (125 mg/ Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry ml papain, 5 mM cysteine HCl, 5 mM disodium EDTA in PBS) at 65°C for 12 h. Sample absorbance at 525 nm was measured using a microplate spectrophotometer (Thermo Scientific) immediately after adding DMMB. Proteoglycan content was calculated based on a standard curve generated using serial dilutions featuring different concentrations of chondroitin sulfate sodium salt (Sigma), and the results are expressed as proteoglycan/DNA (μg/μg) values.
Cell immunofluorescence
To further investigate the effect of LY on NF-κB signalling activated by IL-1β, CEP cells were seeded in 12-well plates (2×10 5 cells/well) and treated with or without 0.4 μΜ LY for 2 h and then stimulated with IL-1β (10 ng/ml) for 30 min. Then the cells were fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100 in PBS for 10 min, incubated (overnight, 4°C) with the aforementioned NF-κB p65 antibody (1:200), washed, and then incubated (1 h, room temperature) with fluorescein isothiocyanate (FITC)-conjugated goat-anti rabbit secondary antibodies (1:200) .
HPLC quantification of LY in rat plasma
As described by Liu et al. [57] and Ren et al. [58] , 6 adult Sprague-Dawley rats received oral or intraperitoneal (i.p.) administration of LY at 5 mg/kg (n = 3/group), and ~0.2 ml blood samples were collected through orbital bleeding via capillary tubes at 30, 60, 120, and 240 min after oral dosing and 10, 30, 60, 120, and 240 min after i.p. dosing. The blood samples were immediately centrifuged at 5000 rpm for 10 min. The LY stock solution contained 1 mg/ml LY in methanol, and working standards were prepared by diluting the stock solution in methanol to obtain LY at 100, 500, 1000, 2500, and 5000 ng/ml. Calibration curves were individually prepared by mixing 2 μl of working standards, 20 μl of blank rat plasma, and 200 μl of methanol. Alternatively, 202 μl of methanol was added to the 20-μl plasma samples. The mixtures were vortexed for 30 s and then centrifuged at 14, 000 rpm for 5 min at room temperature. A 10-μl aliquot of each supernatant was injected into the HPLC system (Waters 2695, USA) for analysis at a flow rate of 1.0 ml/min, and the eluents were detected based on 288 nm absorption. Calibration curves were generated by plotting the peak area (x) against the theoretical concentration (y).
Rat-tail IVD degeneration model
As described by Inoue et al. [59] , surgery for IVD degeneration was performed on the rat-tail Co4-Co5 IVDs, which were located using X-ray. At the corresponding sites in anaesthetized rats, the tip of an 18-G needle was driven to the centre of the NP at a depth of 5 mm from the skin surface. In this position, the needle was turned 360° and retained in this position for 30 s and then stabbed into the cephalic and caudal side of the endplate. A total of 20 8-week-old rats were randomized into four groups (n = 5/group): Sham group, sham operation with i.p. injection of PBS; PBS group, surgery with i.p. injection of PBS; low-dose LY group, surgery with i.p. injection of 2.5 mg/kg LY; and high-dose LY group: surgery with i.p. injection of 5 mg/kg LY. The rats in the four groups were injected every other day for 2 months, after which, the tails were harvested for MRI evaluation and histological analysis.
Histological analysis and histological scores
The rat tails were fixed in paraformaldehyde for 24 h, decalcified for 30 days in EDTA, and then spilt down the mid-sagittal plane and embedded in paraffin. In each case, 3 serial sections (4 μm) were cut and stained with H&E for morphological examination, Picrosirius red staining for collagen type I and collagen type II labelling and Safranin O-fast green for chondrocyte labelling. To exclude the toxic effect of LY, hearts, livers, lungs and kidneys were also fixed in 4% paraformaldehyde for H&E staining.
Three different pathologists, blinded to the treatments, analysed the histological changes according to the criteria of Masuda et al. [60] ; the detailed criteria for histological scoring are listed (see suppl. material) in Suppl. Table 2 . The histological score was calculated as the sum of the degeneration grade of the 3 parameters and ranged from 3 to 9. A total of 9 points indicates severe degeneration, whereas a total of 3 points indicates normal tissue.
The thickness of the cartilage endplate was measured from the cranial growth plate to the border between the nucleus pulposus and the cartilage endplate in the histological samples. For each image, the thickness was determined by an average of 3 measurements obtained in the cartilage endplate. The ratio of cartilage tissue area to the entire endplate was measured and calculated as previously described [48, 61] , and the measurements were assessed by 3 pathologists blinded to the treatments.
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IVD IHC and immunofluorescence analyses
Rat-tail sections were immunostained for ADAMTS-4, ADAMTS-5, MMP-3, MMP-13 and caspase-3 (ab13847) immuno-positive cells were counted under high-power fields in each of the 3 sections from the four groups. Immunofluorescence staining for MIF (ab7207) was also performed as described above.
Statistical analysis
Data were analysed using SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA) and are expressed as the means ± S.D. Student's t test or one-way ANOVA analysis are used to compare differences between two groups or among three or more groups. P < 0.05 was considered statistically significant.
Results
Catabolic protease expression in the CEP of patients with disc degeneration disease
The CEP located between the NP and vertebral bones (Fig. 1A) . To confirm the relationship between IVD and CEP degeneration, we examined normal fractured-IVD CEP and degenerated-IVD CEP specimens (Fig. 1B) . In Safranin O-fast green staining, the normal CEP exhibited homogeneous ECM containing a high density of chondrocytes, whereas the degenerative CEP displayed decreased Safranin O staining in the ECM with a marked decrease in cell density (Fig. 1C) . In addition to reduced cellular and extracellular contents, IHC results showed the increased expression of catabolic proteases, such as ADAMTS-4, ADAMTS-5, MMP-3, and MMP-13, in degenerated-IVD CEP (Fig. 1D, E) . Moreover, the Pfirrmann scores were positively correlated with the mRNA expression in the CEP of ADAMTS-4, ADAMTS-5, MMP-3, and MMP-13 and negatively correlated with the expression of synthetic molecules, such as Sox-9, aggrecan, and Col2a1 (Fig.  1F) . The age of the patient is also an independent risk factor of EP degeneration, and a similar relationship between gene expression and patient age was observed in the present study (see suppl. material, Suppl. Fig. 2 ). Taken together, these data indicated that the expression of catabolic proteases was increased in the CEP of degenerated IVDs in patients. 
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LY inhibits IL-1β-induced expression of ADAMTS-4, ADAMTS-5, MMP-3, and MMP-13 in rat CEP cells
To examine the effect of LY on CEP-derived chondrocytes, we first investigated whether LY exerted any cytotoxic effect on CEP cells. We found no cytotoxic effect of LY when applied at <0.5 μM for 24 and 48 h (Fig. 2A&B) . In addition, LY also did not affect the protein synthesis of Sox-9, Col2a1, and aggrecan in CEP cells when used at a low (0.2 μM) or high (0.2 μM) dose (Fig.  2C ). This finding was further supported by evidence that no obvious cell apoptosis (see suppl. material, Suppl. Fig. 3A and C) or cell cycle arrest was observed after treatment with 0.4 μM of lycorine (see suppl. material, Suppl. Fig. 3B and D) . However, the concentration of LY was important. Cell apoptosis (see suppl. material, Suppl. Fig. 3A and C) and cell arrested in phage S (see suppl. material, Suppl. Fig.  3B and D)were observed after treatment with 4 μM of LY for 48 h. Therefore, concentrations less than 0.4 μM were used for the following experiments. Subsequently, we investigated the role of LY on IL-1β-induced cell degeneration. We observed the mRNA levels of ADAMTS-4, ADAMTS-5, MMP-3, and MMP-13 were significantly upregulated by IL-1β, whilst LY suppressed their expression in a dose-dependent manner (Fig. 2D) . In contrast, the mRNA levels of the anabolic factors, including Sox-9 and aggrecan, were unaffected by IL-1β and LY. Col2a1 expression was slightly, but not statistically significant, repressed by IL-1β and upregulated by LY in a dose-dependent manner (Fig. 2D) . Further, western blotting confirmed the inhibitory effect of LY on the protein levels of ADAMTS-4, ADAMTS-5, MMP-3, and MMP-13 (Fig. 2E, F) . Subsequently, IL-1β reduced glycosaminoglycan content but LY maintained the CEP cell extracellular matrix, evidenced by Alcian blue staining (Fig. 2G ) and DMMB assays (Fig. 2H) . Furthermore, a significant increase of glycosaminoglycan release 
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Cellular Physiology and Biochemistry into the culture medium was induced by IL-1β, and this effect was inhibited by LY (Fig.  2H) . Collectively, these results demonstrated that LY inhibited the expression of catabolic proteases in a dose-dependent manner.
LY inhibits IL-1β-induced NF-κB activation in vitro
To unveil the mechanisms by which LY inhibits IL-1β-induced catabolic protease activity, we examined MAPK and NF-κB pathways. Whereas did not significantly reduce the IL-1β-induced phosphorylation of ERK, P38 or JNK, LY treatment reduced the IL-1β-induced phosphorylation of IκB-α and increased the level of IκB-α (Fig. 3A, B) , suggesting that LY inhibited NF-κB, but not MAPK signalling. Therefore, we examined the upstream regulators of IκB-α (Fig. 3C ) and detected no changes in the phosphorylation of either TAK1 or IKK-α/β, indicating that the phosphorylation of IκB-α was a potential target of LY. Moreover, the factors downstream of IκB-α were further investigated, and we found that IL-1β activated p65 nuclear translocation but LY retained p65 in the cytoplasm (Fig. 3D) . Again, this finding was also confirmed by western blotting, showing p65 mainly in the nuclear extracts in the IL-1β-treated group whereas it was mainly in the cytoplasmic extracts after LY treatment (Fig. 3E) . To ensure the involvement of NF-κB cascades in LY treatment, we explored NF-κB luciferase-activity assay and revealed that the luciferase-reporter activity stimulated by IL-1β was also reduced by LY in a dose-dependent manner (Fig. 3F) . Lastly, to "rescue" the inhibited degradation of IκB-α by LY, we overexpressed IKK-β and observed increased expression of ADAMTS-4, ADAMTS-5, MMP-3, and MMP-13 (Fig. 3G) . These results indicated that LY suppressed IL-1β-induced expression of catabolic proteases mainly by inhibiting NF-κB signalling (Fig. 3H) .
Quantification of LY levels in rat plasma
Based on the protective effect of LY on CEP chondrocytes in vitro, we proposed that this compound might exert a protective effect on CEP degeneration in vivo. Thus, we examined 
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Cellular Physiology and Biochemistry the concentration of LY in rat plasma as an initial step. We measured the concentration of LY in rat plasma samples after the oral and intraperitoneal (i.p.) administration of 5 mg/kg LY. The LY retention time in HPLC analysis was ~13.5-15.5 min (Fig. 4A) , and a complete absorption-spectrum scan revealed that the LY absorption maximum was at 288 nm (Fig.  4B) . The calibration curves for all matrices showed good linearity (R 2 = 0.99) over the LY concentration ranges in the plasma (Fig. 4C) . The mean plasma concentration vs. time profiles of LY revealed that after both oral and i.p. administration, LY reached the effective drug dose as in the in vitro study (Fig. 4D) . 
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LY prevents CEP degeneration in a rat-tail model of IVD degeneration
To determine whether LY acts on the CEP, we examined the changes in the CEP in the rats of the four experimental groups used in this study. No obvious toxic effect was observed after LY treatment, evidenced by the normal morphology of major target organs after intraperitoneal administration of 5 mg/kg every other day for 2 months (see suppl. material, Suppl. Fig. 3E ). Regarding the effect of LY on CEP, H&E staining revealed a well-structured hyaline cartilage and homogeneous ECM in the sham group, whereas a disorganized matrix featuring a thinner CEP tissue and comparatively fewer cells was observed in the PBS-treated group, which confirmed CEP degeneration (Fig. 5A) . The PBS group also exhibited sclerosis and ossification in safranin O-fast green staining (Fig. 5B) . However, after LY administration, the CEP structure, cell number, and proteoglycan content recovered in a dose-dependent manner. On picrosirius red-stained sections, endplate zone in PBS group contained higher areas of bright orange staining (collagen I; shown as red arrow) and corresponding decrease in green staining (collagen II; shown as green arrow) area under polarized light compared to that in the sham group. More importantly, the administration of LY presented with higher type II collagen and lower type I collagen (Fig. 5C ). Furthermore, in the PBS group, the endplate thickness and the proportion of endplate chondrocytes in the CEP area were markedly lower than those in the sham group, and both of these measures were significantly higher in the low-dose and high-dose LY groups compared to those in the PBS group ( Fig. 5D and E) .
Next, IHC analysis was used to examine the matrix-degrading enzymes in CEP tissues from the four groups. Consistent with the in vitro results, immunostaining for ADAMTS-4, ADAMTS-5, MMP-3, and MMP-13 in the rat-tail CEP was higher in the PBS group than that in the sham group and decreased in both the low-dose and high-dose LY groups (Fig. 6A-D) . 
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These results suggested that LY prevents CEP degeneration in the rat-tail model. Apoptosis has also been associated with degeneration. Interestingly, we also found that the apoptosis marker caspase-3 was also decreased by LY (see suppl. material, Suppl. Fig. 4 ).
LY effectively prevents IVD degeneration in the rat-tail model
Further MRI results obtained at 8 weeks after the i.p. administration of LY confirmed that the model was successfully established and LY inhibited the degeneration of IVDs (Fig.  7A) . H&E staining revealed increased numbers of tears and clefts in NP tissues in the PBS group when compared with the sham group. However, after LY administration, the detection of clefts decreased (Fig. 7B) . Compared with the sham group, the PBS group showed a reduction in cells and obvious ruptured fibres in the annulus fibrosus, but the low and high LY doses reversed these changes (Fig. 7C) . Alcian blue staining indicated that the content of proteoglycans was diminished in the PBS group, but increased after LY administration (Fig.  7D) . Overall, the histological score of the PBS group was significantly higher than that of the sham group (Fig. 7E) . However, after LY treatment, the histological score was decreased in the low-dose group and the high-dose group. Collectively, these results demonstrated that LY, directly or indirectly, protected against IVD degeneration in vivo.
LY prevents IVD degeneration by inhibiting MIF release by the endplate in the rat-tail model
To further investigate the effect of LY on IVD degeneration, we first tested the effect of LY on NP cells in vitro. The results of CCK-8 assays showed that when 0-16 μM LY was 5B ). Furthermore, Alcian blue staining and DMMB assays showed that the ECM glycosaminoglycan content decreased after IL-1β stimulation but did not obviously recover after LY addition. Moreover, the IL-1β-induced increase of glycosaminoglycan release into the culture medium was also not inhibited by LY (see suppl. material, Suppl. Fig. 5C and D) . These results indicated that LY does not exert a direct protective effect on NP cells. Therefore, we proposed that LY might play an indirect role on IVD via CEP. The results of in vitro studies showed that TNF-α, IL-1β, and IL-6 exhibited parallel expression changes in CEP and NP cells: the expression was upregulated after IL-1β stimulation and this upregulation was curtailed by LY. Importantly, the expression of MIF, a proinflammatory cytokine, was detected only in CEP cells (Fig. 8A) . Consistent with the qPCR results, western blotting detected abundant MIF expression in CEP cell extracts but not in NP cell extracts (Fig. 8B) . Consistently, in IVD immunofluorescence analysis, MIF staining in the CEP was higher in the PBS group than that in the sham group, but the staining was decreased in both low-dose and high-dose LY groups (Fig. 8F) . Thus, we speculated that inhibition of MIF release by the endplate represents one of the mechanisms by which LY effectively prevents IVD degeneration in the rat-tail model.
Discussion
The present study demonstrated for the first time that LY could potentially be used for treating IVD degeneration. CEP degeneration plays a pivotal in IVD disease [62, 63] . LY suppressed the IL-1β-induced upregulation of ADAMTS-4, ADAMTS-5, MMP-3, and MMP-13 in endplate chondrocytes by blocking the NF-κB pathway. Subsequently, LY protected the degradation of extracellular matrix and thereby directly prevented CEP degeneration. Interestingly, the prevention of CEP degeneration would indirectly protect IVD degeneration via the suppression of MIF release from the CEP into the NP. Indeed, this finding is consistent with that of a previous study showing that LY can suppress the IL-1β-induced expression of MMP-3 and MMP-13 in articular chondrocytes [55] . The present study reveals a further 
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Cellular Physiology and Biochemistry function of LY in addition to its known pharmacological effects, such as anti-tumour [51] , antiviral [52] , and anti-inflammatory [53, 54] effects. IL-1β participates in IVD degeneration by increasing protease expression in the CEP. Regarding the origin of IL-1β, Tang et al. reported that the NLRP3/caspase-1/IL-1β axis is active in the CEP of patients with endplate degeneration and that IL-1β can be secreted by the CEP [18] . IL-1β was also detected in the culture medium of degenerating CEP cells [5] , and IL-1β was produced by both IVD cells and immune cells [14, 16] . Thus, the pathological processes during IVD and endplate degeneration mutually promote each other, and the initial inflammatory reaction mediated by IL-1β can be self-amplified. NF-κB was previously reported to play a key role in IVD degeneration, and NF-κB inhibition reversed IL-1β-induced changes in the expression of ADAMTS-4, ADAMTS-5, MMP-3, and MMP-13 [7, 8, 64] . The present results showed that LY decreased the IL-1β-stimulated expression of these catabolic proteases in CEP cells by inhibiting the NF-κB signalling pathway.
To investigate the in vivo effect of LY on the CEP, we constructed a rat-tail model of IVD degeneration, in which LY exerted a clear protective effect on the CEP. Vascular channels [41] [42] [43] that bring nutrients to both the avascular IVD [36, 65] and the CEP itself have been identified in the vertebral endplate. The size of the vascular channels might be implicated in IVD degeneration [66] . Interruption of blood supply through peripheral microcirculation to the CEP might cause apoptosis of CEP chondrocytes [67] , and the IVD degeneration model can be established by inducing an ischaemic sub-endplate [35, 36] . Thus, the vascular buds might serve as the route for transporting LY into the CEP, and the present results showed that LY suppressed the degeneration process in the CEP in the IVD degeneration model.
In addition, LY exerted an indirect protective effect on the NP. As no direct drug effect was found in NP cells in vitro, the observed alleviation of NP degeneration could be ascribed to reduced MIF production and reduced downstream inflammatory cytokine production in the CEP after LY treatment. This finding is consistent with that of Neidlinger, who demonstrated that the dysfunctional CEP tissue could provide proinflammatory mediators or cytokines, such as MIF, IL-1β, TNF-α, and IL-6, and influence matrix degradation in CEP and NP tissues [5] . Importantly, the degenerated NP is a biologically active tissue that can respond to proinflammatory factors, and the NP also produces cytokines, such as TNF-α, IL-1β, IL-1α, IL-2, IL-4, IL-6, and prostaglandin E2, after simulation by proinflammatory factors, which in turn promote the progression of pathological changes in degenerated discs [24, 68] .
MIF is recognized as a multipotent cytokine involved in the pathogenesis of several inflammatory diseases [5, 69] . The MIF-CD74 signal elicits an imbalance between anabolic and catabolic metabolism in the CEP [39] and stimulates the release of TNF, IL-1, IL-6, and IL-8 [70] . Furthermore, promoter analysis revealed that two NF-κB binding sites are present in the MIF proximal promoter region and that MIF expression can be induced in an NF-κB-dependent manner [71] . Thus, in the present study the reduction of MIF expression after LY treatment is likely due to the suppressed NF-κB signalling pathway.
We found that NF-κB signalling modulated the expression of all four aforementioned factors, and IL-1β-induced upregulation of IL-6, TNF-α, and IL-1β was constrained by LY through NF-κB inhibition in CEP and NP cells; however, MIF overexpression was induced by IL-1β mainly in CEP cells. These findings indicate that MIF might serve as an optimal molecule for monitoring the molecular interaction between CEP and NP tissues. Immunostaining revealed that MIF was positively stained in the CEP in degenerated discs, and this effect was inhibited by LY administration. We speculated that the LY-mediated inhibition of the release of proinflammatory factors and cytokines from the CEP into the NP could explain the delay in the IVD degeneration process after LY treatment.
Lycorine is extensively studied as an anti-tumour drug and has been demonstrated to have effects on the induction of cell apoptosis [72] [73] [74] [75] [76] [77] , autophagy [78] and cell cycle arrest [79, 80] in different tumour cell lines. Thus, in the present study, the toxicity of lycorine on endplate cells was carefully assessed, and we found that CEP cells showed no obvious apoptosis or cycle arrest effect at 0.4 μM LY, as this dose is much lower than the anti-tumour effect dose (4-50 μM) used in previous studies. Additionally, no obvious morphological Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry changes were found in the major organs in animal models. Although little toxicity on CEP cells was observed in the present study, we have to admit that it is difficult to recommend the long-term intraperitoneal use of LY in the clinic. However, we propose that the present study would further enlighten other scientist to modify the structure of LY and thus promote its future clinical application.
There are several limitations in the present study. First, we only used CEP and NP cells; IVD degeneration also involves the remodelling of the subchondral bone and annulus fibrosus cells, and thus further investigation must be conducted to examine how LY affects these cells. Second, there was no functional assessment of the effect of lycorine on disc degeneration, such as the pain status of the rats.
In summary, the present results indicated that LY rescued IVD degeneration by inhibiting the expression of MMP-3, MMP-13, and ADAMTS-5 in endplate chondrocytes through inhibiting the NF-κB pathway. Moreover, LY treatment also reduced positive regulators of proinflammatory cytokines, such as MIF, that can be secreted by CEP cells and target to NP cells. Thus, LY might represent a potential therapeutic drug for IVD degeneration.
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